Parkinson's disease, levodopa-use and the risk of melanoma.

There is no fulltext present in this item.

Title:	Parkinson's disease, levodopa-use and the risk of melanoma.
Author(s):	Vermeij, J.D.; Winogrodzka, A.; Trip, J.; Weber, W.E.
Publication year:	2009
Source:	Parkinsonism & Related Disorders, vol. 15, iss. 8, (2009), pp. 551-553
ISSN:	1353-8020
DOI:	https://doi.org/10.1016/j.parkreldis.2009.05.002
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/189326
Display more details
Subject:	DCN 1: Perception and Action
Organization:	Neurology
Journal title:	Parkinsonism & Related Disorders
Volume:	vol. 15
Issue:	iss. 8
Page start:	p. 551
Page end:	p. 553
Abstract:	Since the early 1970s, the literature has suggested an association between Parkinson's Disease (PD) and/or levodopa-use and an increased risk for the development of malignant melanoma. In some countries, this possible association has even led to a warning in the drug insert leaflet of the possible risk. Recently, five studies have been published that have investigated both associations and three conclusions can be drawn. Firstly, there appears to be an increased risk in the development of melanomas in patients with PD. Secondly, this increased risk is already present before the PD is diagnosed. Finally, it is unlikely that levodopa plays any role in this phenomenon. It is not known which factors are responsible for this increase in the development of melanomas in PD patients and this needs further investigation. We recommend the removal of the warning from the drug insert leaflet, since this can lead to unnecessary fear on the part of the patients and physician resistance to prescribing this medication.